Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.
Chemomab Therapeutics Ltd. (CMMB) generates news primarily as a clinical-stage biotechnology company developing nebokitug, a monoclonal antibody targeting the soluble protein CCL24 in fibro-inflammatory diseases. Much of the company’s news flow centers on clinical data, regulatory interactions and scientific presentations related to primary sclerosing cholangitis (PSC), a rare and progressive liver disease with no effective medical therapy other than liver transplantation in advanced cases.
Investors and observers following Chemomab news can expect detailed updates on the Phase 2 SPRING trial of nebokitug in PSC, including results from the double-blind, placebo-controlled portion and the open label extension, where patients received nebokitug for up to 48 weeks. Press releases describe safety and tolerability findings, changes in biomarkers such as ELF score, PRO-C3 and liver stiffness measurements, and analyses in subgroups with moderate or advanced fibrosis. These reports often highlight biomarker patterns that are associated with PSC disease progression and transplant-free survival.
Chemomab’s news also covers regulatory milestones, such as outcomes of End-of-Phase 2 meetings with the FDA, alignment on a single Phase 3 registration trial design using a composite of clinically relevant events, and agreements on Chemistry, Manufacturing and Controls (CMC) and nonclinical toxicology requirements. Additional announcements address Orphan Drug and Fast Track designations for nebokitug, as well as the status of an open U.S. IND for systemic sclerosis.
Another recurring theme in Chemomab’s news releases is its scientific and investor outreach. The company reports oral and poster presentations at major liver and gastroenterology meetings, including Digestive Disease Week, BSG Live, AASLD The Liver Meeting and EASL congresses, where nebokitug data and CCL24-related mechanisms are discussed. Chemomab also announces participation in rare disease summits and global investment conferences, along with corporate updates tied to quarterly financial results, patent awards and capital markets activities such as at-the-market equity offerings or ADS ratio adjustments.
Readers of the CMMB news page on Stock Titan can use this stream of clinical, regulatory and corporate announcements to track Chemomab’s progress with nebokitug in PSC and other fibro-inflammatory indications, as well as to monitor key events that may influence the company’s development plans and regulatory trajectory.
Chemomab Therapeutics (Nasdaq: CMMB) has announced its participation in the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025. CEO Dr. Adi Mor and senior management will deliver a corporate presentation at 8:00 am ET, which will be webcast live and available on the company's website for 90 days.
Chemomab is advancing CM-101, a first-in-class monoclonal antibody targeting CCL24, for fibro-inflammatory diseases. The company recently reported positive results from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC). Two key milestones are expected in early 2025: establishing an FDA registrational pathway for CM-101's Phase 3 pivotal trial and reporting data from the SPRING trial open label extension.
The company plans to initiate the PSC Phase 3 trial by year-end. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC treatment. Additionally, their CM-101 program for systemic sclerosis is Phase 2-ready with an open U.S. IND.
Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotech company focused on fibro-inflammatory diseases, announces its participation in Oppenheimer's Movers in Rare Disease Summit on December 12, 2024, at the Westin Grand Central in New York City. The invitation-only event will showcase companies with potential near-term stock-moving catalysts through panels, presentations, and one-on-one investor meetings. Chemomab's management will deliver an Elevator Pitch at 2:45-3:30 pm EST and will be available for individual meetings with registered attendees.
Chemomab Therapeutics presented Phase 2 SPRING trial data for CM-101 in primary sclerosing cholangitis (PSC) at AASLD The Liver Meeting® 2024. The trial, involving 76 patients, tested two doses (10 mg/kg and 20 mg/kg) administered every three weeks over 15 weeks. CM-101 met its primary safety endpoint and showed dose-dependent improvements across multiple biomarkers. The higher 20 mg/kg dose demonstrated greater improvements, particularly in patients with moderate/advanced disease, showing anti-fibrotic, anti-inflammatory, and anti-cholestatic effects. Key improvements were observed in liver stiffness, ELF scores, PRO-C3 levels, liver biochemistries, bilirubin levels, and pruritus scores.
Chemomab Therapeutics (Nasdaq: CMMB) reported Q3 2024 financial results and announced key developments. The company has scheduled an FDA End-of-Phase 2 Meeting in Q4 2024 to discuss CM-101's Phase 3 trial design for Primary Sclerosing Cholangitis (PSC). Their cash position stands at $19.5 million as of September 30, 2024, with runway extended to early 2026 following a $10 million private placement. Q3 net loss was $3.5 million, with R&D expenses at $2.8 million and G&A expenses at $0.9 million. The company reported positive Phase 2 SPRING trial results for CM-101 in PSC patients, with plans to advance to Phase 3 in late 2025.
Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotech company focused on fibro-inflammatory disease treatments, announced it will release its Q3 2024 financial results and business update on November 14, 2024, at 7:00 am ET. Investors interested in discussing the results after the release can contact the company via IR@chemomab.com.
Chemomab Therapeutics (Nasdaq: CMMB) announced that its late-breaking abstract on the Phase 2 SPRING trial results for CM-101 in primary sclerosing cholangitis (PSC) has been selected for an oral presentation at the AASLD The Liver Meeting® 2024. The conference will be held in San Diego from November 15-19, 2024.
Professor Christopher Bowlus, MD, FAASLD, from the University of California Davis School of Medicine, will present the data from the double-blinded portion of the trial. The presentation, titled 'CM-101 improved fibrosis biomarkers in patients with primary sclerosing cholangitis: The Phase 2 SPRING Study', is scheduled for November 18, 2024, from 2:45-3:00pm PT during the Late Breaking Abstract Parallel Session 1.
Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotechnology company focused on fibro-inflammatory diseases, has announced its participation in two upcoming investor conferences. The company will attend the Third Annual ROTH Healthcare Opportunities Conference on October 9, 2024, in New York City, where management will meet with investors. Additionally, CEO Dr. Adi Mor will participate in a fireside chat at the Maxim Healthcare Virtual Summit on October 16, 2024, at 9:00 am ET.
The ROTH conference will feature one-on-one meetings with investors, while the Maxim Healthcare Summit will include a virtual fireside chat. A recording of the Maxim Summit fireside chat will be made available on Chemomab's investor relations website after the event. Both conferences are invitation-only events.
Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotechnology company focused on fibro-inflammatory diseases, has announced upcoming investor conference presentations. CEO Dr. Adi Mor will deliver corporate presentations at two events:
1. H.C. Wainwright 26th Annual Global Investment Conference: A prerecorded webcast available from September 9, 2024, at 7:00 am ET for 90 days.
2. HBM Biopharma Summit 2024 in Zurich, Switzerland: A live in-person presentation scheduled for September 23, 2024, at 10:45 am CET at the Park Hyatt Zurich.
The H.C. Wainwright presentation will be accessible via webcast, while the HBM Summit presentation will not be webcast. These presentations offer investors insights into Chemomab's innovative therapeutics for high unmet need fibro-inflammatory diseases.
Chemomab Therapeutics (Nasdaq: CMMB) reported positive Phase 2 results for CM-101 in Primary Sclerosing Cholangitis (PSC), demonstrating safety and anti-fibrotic, anti-inflammatory, and anti-cholestatic activity. The company completed a $10 million PIPE financing, extending its cash runway through early 2026. Key highlights include:
- CM-101 met primary and secondary endpoints in the SPRING trial
- First therapy to show broad effects on PSC's main components
- Statistically significant reduction in liver stiffness after 15 weeks
- Planning for Phase 3 PSC trial and FDA discussions
- Q2 2024 financials: $12.8 million cash position, $2.9 million R&D expenses, $0.8 million G&A expenses
- Net loss of $3.6 million or $0.01 per share
Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, has announced that it will release its second quarter 2024 financial results on August 21, 2024, at 7:00 am Eastern Time. The company will also provide a business update along with the financial report. Investors interested in discussing the financial results or business update after the earnings release can contact the company at IR@chemomab.com.